Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Capital Expenditures: 2013-2017

Historic Capital Expenditures for Tvardi Therapeutics (TVRD) over the last 3 years, with Sep 2017 value amounting to $28,000.

  • Tvardi Therapeutics' Capital Expenditures fell 94.29% to $28,000 in Q3 2017 from the same period last year, while for Sep 2017 it was $127,000, marking a year-over-year decrease of 80.61%. This contributed to the annual value of $1.0 million for FY2024, which is 55.96% down from last year.
  • Tvardi Therapeutics' Capital Expenditures amounted to $28,000 in Q3 2017, which was up 27.27% from $22,000 recorded in Q2 2017.
  • Tvardi Therapeutics' 5-year Capital Expenditures high stood at $490,000 for Q3 2016, and its period low was $1,000 during Q4 2013.
  • Moreover, its 3-year median value for Capital Expenditures was $22,000 (2017), whereas its average is $72,273.
  • Per our database at Business Quant, Tvardi Therapeutics' Capital Expenditures tumbled by 95.24% in 2015 and then soared by 48,900.00% in 2016.
  • Tvardi Therapeutics' Capital Expenditures (Quarterly) stood at $1,000 in 2013, then soared by 1,400.00% to $15,000 in 2014, then plummeted by 53.33% to $7,000 in 2015, then skyrocketed by 885.71% to $69,000 in 2016, then tumbled by 94.29% to $28,000 in 2017.
  • Its last three reported values are $28,000 in Q3 2017, $22,000 for Q2 2017, and $8,000 during Q1 2017.